Viewing immunotherapy resistance through RNA regulation

A review has summarized mechanisms by which alternative splicing of immune checkpoint molecules contributes to cancer immune evasion and resistance to immune checkpoint blockade (ICB). Lu, Guo, and Jia classified splicing events that alter checkpoint molecule structure and function, and discussed their potential use as biomarkers and therapeutic targets. This is a literature review synthesizing existing studies, not a clinical trial testing treatment efficacy in a new patient population.

The clinical efficacy of ICB is limited by primary resistance, in which there is no response from the outset, and acquired resistance, which develops during treatment. The review offers a perspective for understanding this resistance by examining the different forms in which immune checkpoint molecules are produced and how their functions vary with those forms.

Splicing that changes checkpoint molecule structure

Alternative splicing is a gene expression regulatory process in which differences in post-transcriptional RNA processing produce distinct forms of a gene product. The review systematically classified immune checkpoint splicing by its occurrence patterns, evolutionary conservation, affected protein regions, and functional effects. It highlighted splicing of exons encoding transmembrane regions as a notable feature.

The researchers described how dysregulation of the spliceosome—the complex that carries out splicing—as well as cis-acting elements and trans-acting factors contribute to these changes in the tumor microenvironment. The abstract states that this process affects ligand–receptor interactions and subsequent immune signaling. However, it does not specify the direction of change for individual checkpoints or provide detailed experimental results, so these events cannot all be generalized as mechanisms that block signaling in the same way.

Uses of soluble forms and targeting splicing

The review discussed the use of soluble isoforms as diagnostic and prognostic biomarkers. Isoforms are distinct molecular forms derived from the same gene; here, the focus is on soluble forms. It also described combination strategies using oncolytic viruses engineered to express soluble decoys. However, the provided abstract alone does not establish which isoforms are useful in which cancers or how accurate the biomarkers are.

Approaches presented for directly targeting aberrant splicing include antisense oligonucleotides, splicing modulators, RNA interference, and CRISPR/Cas systems. These are approaches whose therapeutic potential the review discusses. The abstract does not give specific experimental conditions, effect sizes, or stages of clinical development for each strategy, so they should not be interpreted as treatments shown to overcome resistance in patients.

A framework linking research strategies and remaining validation needs

The review’s contribution is to connect the classification of immune checkpoint splicing, its regulatory mechanisms, and potential biomarker and therapeutic applications in a single framework. It does not establish a single mechanism as the cause of resistance or demonstrate the clinical efficacy of correcting splicing.

The provided material contains no patient characteristics, sample sizes, comparator groups, endpoints, follow-up periods, or quantitative treatment outcomes. Assessing the performance of a particular biomarker or the utility of a targeted treatment requires examining the design and results of the individual primary studies. Accordingly, this paper is best read as a synthesis of questions and candidate strategies for follow-up research, rather than evidence that can be applied directly to treatment selection.

This article is based on the provided bibliographic information and abstract of a review published in Critical Reviews in Oncology/Hematology.